To explore the dose-response relationship between pharmacokinetics and pharmacodynamics of Y- Shaped Pegylated growth hormone injection (YPEG-GH) in children with short stature (idiopathic short stature (ISS), small for gestational age (SGA), Turner syndrome (TS)). To evaluate its tolerability, safety and efficacy and to provide evidence for dose selection and titration for future clinical development and clinical application in these population.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacokinetic-area under plasma concentration versus time curve
Timeframe: up to 52 weeks
Pharmacokinetic-maximum serum concentration
Timeframe: up to 52weeks
Pharmacokinetic-time to reach the maximum plasma concentration
Timeframe: up to 52 weeks
Pharmacokinetic-terminal disposition phase half-life
Timeframe: up to 52 weeks
Pharmacokinetic-terminal elimination rate constant
Timeframe: up to 52 weeks
Pharmacokinetic-apparent clearance after extravascular administration
Timeframe: up to 52 weeks
Pharmacokinetic-apparent volume of distribution
Timeframe: up to 52 weeks